Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Asthma: Pathogenesis and Management01:20

Asthma: Pathogenesis and Management

1.4K
Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
1.4K
COPD: Pathogenesis and Clinical Features01:20

COPD: Pathogenesis and Clinical Features

1.9K
Chronic obstructive pulmonary disease (COPD) is a group of lung conditions that progressively worsen over time, including chronic bronchitis and emphysema. This cluster of diseases collectively leads to a gradual and irreversible decline in lung function over time.
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
1.9K
Esophageal Perforation-II: Clinical Manifestations and Management01:28

Esophageal Perforation-II: Clinical Manifestations and Management

738
Esophageal perforations manifest in various clinical forms, influenced by factors such as the perforation's cause and location (cervical, intrathoracic, or intra-abdominal), the extent of contamination, and potential injury to adjacent mediastinal structures. The timing between the perforation occurrence and treatment initiation also affects the clinical presentation.
Clinical Manifestations:
738
Barrett Esophagus-II: Clinical Manifestations and Management01:21

Barrett Esophagus-II: Clinical Manifestations and Management

1.1K
Individuals with Barrett's esophagus are often asymptomatic, but they may experience symptoms commonly associated with GERD, such as heartburn and acid regurgitation. Additional symptoms can include difficulty swallowing, chest pain, unintentional weight loss, blood in the stool (which may appear black, tarry, or bloody), and episodes of vomiting.
To diagnose Barrett's esophagus, healthcare providers often recommend an endoscopy for those showing symptoms of acid reflux. The procedure...
1.1K
Esophageal Varices-II: Clinical Features and Management01:28

Esophageal Varices-II: Clinical Features and Management

597
Esophageal varices often manifest as gastrointestinal bleeding episodes, presenting symptoms like hematemesis (vomiting of blood), hematochezia (passing fresh blood via the rectum), and melena (black, tarry stools). Other signs can include weight loss, anorexia, abdominal discomfort, jaundice, pruritus, altered mental status, and muscle cramps.
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol...
597
Gastritis III: Clinical Manifestations and Management01:23

Gastritis III: Clinical Manifestations and Management

1.3K
The clinical manifestations of gastritis can vary depending on the cause and type of gastritis, but some common symptoms may include the following.
Clinical manifestations of acute gastritis
The patient with acute gastritis may have a rapid onset of symptoms, such as epigastric pain or discomfort, dyspepsia, anorexia, hiccups, or nausea and vomiting, which can last from a few hours to a few days. Erosive or hemorrhagic gastritis may cause bleeding, which may manifest as blood in vomit or as...
1.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Efficacy and safety of recombinant activated factor VII for secondary prophylaxis in patients with Glanzmann thrombasthenia.

Research and practice in thrombosis and haemostasis·2026
Same author

Multicenter Interlaboratory Study of Thrombin Generation Assay in Healthy Adults Using the ST Genesia Analyzer With the STG-ThromboScreen Reagent (With and Without Thrombomodulin).

International journal of laboratory hematology·2026
Same author

TMEM145 is a principal component of outer hair cell stereocilia.

Neuron·2026
Same author

Cross-species validation of a human age-related hearing loss candidate KLHDC7B as essential for mammalian hearing.

Communications biology·2025
Same author

C57BL/6-derived mice and the Cdh23<sup>ahl</sup> allele - Background matters.

Hearing research·2025
Same author

Real world outcomes of momelotinib in myelofibrosis patients with anemia: results from the MOMGEMFIN study.

Blood cancer journal·2025

Related Experiment Video

Updated: Feb 7, 2026

Minimizing Post-Infusion Portal Vein Bleeding during Intrahepatic Islet Transplantation in Mice
06:41

Minimizing Post-Infusion Portal Vein Bleeding during Intrahepatic Islet Transplantation in Mice

Published on: May 10, 2021

4.4K

Ibrutinib-related bleeding: pathogenesis, clinical implications and management.

Carlos Aguilar1

  • 1Department of Haematology, Hospital General Santa Barbara, Paseo Santa Bárbara s/n, Soria, Spain.

Blood Coagulation & Fibrinolysis : an International Journal in Haemostasis and Thrombosis
|July 12, 2018
PubMed
Summary

Ibrutinib, a Bruton's tyrosine kinase (Btk) inhibitor, increases bleeding risk in B-cell malignancies due to complex antiplatelet effects. Careful antithrombotic therapy selection and individualized treatment are crucial for managing this risk.

More Related Videos

Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice
08:13

Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice

Published on: September 30, 2021

7.5K
Antibody Transfection into Neurons as a Tool to Study Disease Pathogenesis
06:56

Antibody Transfection into Neurons as a Tool to Study Disease Pathogenesis

Published on: September 26, 2012

11.1K

Related Experiment Videos

Last Updated: Feb 7, 2026

Minimizing Post-Infusion Portal Vein Bleeding during Intrahepatic Islet Transplantation in Mice
06:41

Minimizing Post-Infusion Portal Vein Bleeding during Intrahepatic Islet Transplantation in Mice

Published on: May 10, 2021

4.4K
Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice
08:13

Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice

Published on: September 30, 2021

7.5K
Antibody Transfection into Neurons as a Tool to Study Disease Pathogenesis
06:56

Antibody Transfection into Neurons as a Tool to Study Disease Pathogenesis

Published on: September 26, 2012

11.1K

Area of Science:

  • Oncology
  • Hematology
  • Pharmacology

Background:

  • Ibrutinib is a novel Bruton's tyrosine kinase (Btk) inhibitor used for B-cell lymphoid malignancies.
  • Clinical trials indicate an increased bleeding risk associated with ibrutinib, particularly when combined with warfarin.

Purpose of the Study:

  • To elucidate the complex antiplatelet mechanisms underlying ibrutinib-associated bleeding.
  • To provide guidance on managing bleeding risk and antithrombotic therapy in patients receiving ibrutinib.

Main Methods:

  • Review of clinical trial data and pharmacological mechanisms of ibrutinib.
  • Analysis of platelet signaling pathways affected by Btk and Tec inhibition.
  • Evaluation of antithrombotic therapy options in the context of ibrutinib use.

Main Results:

  • Ibrutinib inhibits Btk and Tec kinases, impairing platelet activation.
  • Concomitant antiplatelet and anticoagulant therapies significantly increase bleeding risk.
  • Aspirin and direct oral anticoagulants are preferred antithrombotic agents if needed.

Conclusions:

  • Ibrutinib's bleeding risk is multifactorial, involving inhibition of key platelet kinases.
  • Individualized assessment of antithrombotic therapy is essential for patients on ibrutinib.
  • Management of major bleeding involves drug withdrawal and platelet transfusion.